@article{480b2b85339a48ea9a1efb7a13b96873,
title = "Non-palliative radiotherapy in ab initio oligometastatic prostate cancer: an Italian national survey: Radiologia Medica",
abstract = "Aims: The purpose of this survey was to investigate the current opinion among Italian radiation oncologists regarding the non-palliative radiotherapy in ab initio oligometastatic prostate cancer (OMPC) patients. Methods: A link to complete the survey was sent via e-mail to Italian radiation oncologists on February 2018. It was requested that only one physician per facility completed the survey, and that he/she was dedicated to PC management in his/her daily clinical practice. The questionnaire consisted of 15 questions concerning the management of OMPC. Results: One hundred and eleven radiation oncologists filled in the questionnaire. The majority of them see ≤ 10 patients affected by OMPC in a year. More than 80% of respondents would perform radiotherapy (RT) to both the prostate and all metastases sites, but mostly up to 2–3 metastases; furthermore, > 80% of physicians would perform RT on both nodal and bone secondary lesions. Most respondents deem a choline- or prostate-specific membrane antigen (PSMA)-positron emission tomography (PET) mandatory before considering a patient affected by OMPC for non-palliative RT. The association of RT with androgen deprivation therapy for at least 12 months would be recommended by > 50% of respondents. In the follow-up phase, the majority would suggest a clinical examination and PSA every 3–6 months and a choline- or PSMA-PET only at biochemical progression. More than 90% of respondents confirmed to be interested in participating in a multicentre study regarding this subject. Conclusions: This survey investigated the current opinion of Italian radiation oncologists and confirmed their interest in OMPC management. {\textcopyright} 2018, Italian Society of Medical Radiology.",
keywords = "Oligometastatic, Prostate cancer, Radiotherapy, Survey, clinical practice, health care survey, human, Italy, male, metastasis, pathology, prostate tumor, radiation oncology, Health Care Surveys, Humans, Male, Neoplasm Metastasis, Practice Patterns, Physicians', Prostatic Neoplasms, Radiation Oncology",
author = "G. Timon and B.A. Jereczek-Fossa and S. Fersino and C. Iotti and R. Corv{\`o} and S.M. Magrini and F. Alongi",
note = "Cited By :1 Export Date: 2 March 2020 CODEN: RAMEA Correspondence Address: Timon, G.; Radioterapia Oncologica, Azienda Unit{\`a} Sanitaria Locale - IRCCS di Reggio EmiliaItaly; email: giorgiatimon@gmail.com References: Vale, C.L., Fisher, D.J., White, I.R., What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis (2018) Ann Oncol, 29 (5), pp. 1249-1257; Gravis, G., Gravis, G., Boher, J.M., Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHAARTED and GETUG-AFU15 studies (2018) Eur Urol, 73 (6), pp. 847-855; Heidenreich, A., Bastian, P.J., Bellmunt, J., EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013 (2014) Eur Urol, 65, pp. 124-137; Arcangeli, S., Zilli, T., De Bari, B., Alongi, F., Hit the primary”: a paradigm shift in the treatment of metastatic prostate cancer? (2016) Crit Rev Oncol Hematol, 97, pp. 231-237; Koo, K.C., Dasgupta, P., Treatment of oligometastatic hormone-sensitive prostate cancer: a comprehensive review (2018) Yonsei Med J, 59 (5), pp. 567-579; Gillessen, S., Attard, G., Beer, T.M., Management of patients with advanced prostate cancer: the report of the advanced prostate cancer consensus conference APCCC 2017 (2018) Eur Urol, 73 (2), pp. 178-211; Francini, E., Gray, K.P., Xie, W., Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC) (2018) Prostate, 78 (12), pp. 889-895; Pillay, B., Wootten, A.C., Crowe, H., The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: a systematic review of the literature (2016) Cancer Treat Rev, 42, pp. 56-72; Rao, K., Manya, K., Azad, A., Uro-oncology multidisciplinary meetings at an Australian tertiary referral centre—impact on clinical decision-making and implications for patient inclusion (2014) BJU Int, 114, pp. 50-54; Kurpad, R., Kim, W., Rathmell, W.K., A multidisciplinary approach to the management of urologic malignancies: does it influence diagnostic and treatment decisions? (2011) Urol Oncol, 29 (4), pp. 378-382; (2011) National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, , http://www.nccn.org, version 3.2018. National Comprehensive Cancer Network, Jenkintown; Pasoglou, V., Larbi, A., Collette, L., One-step TNM staging of high-risk prostate cancer using magnetic resonance imaging (MRI): toward an upfront simplified “all-in-one” imaging approach? (2014) Prostate, 74 (5), pp. 469-477; Larbi, A., Dallaudi{\`e}re, B., Pasoglou, V., Whole body MRI (WB-MRI) assessment of metastatic spread in prostate cancer: therapeutic perspectives on targeted management of oligometastatic disease (2016) Prostate, 76 (11), pp. 1024-1033; Joice, G.A., Rowe, S.P., Pienta, K.J., Gorin, M.A., Oligometastatic prostate cancer: shaping the definition with molecular imaging and an improved understanding of tumor biology (2017) Curr Opin Urol, 27 (6), pp. 533-541; Hellman, S., Weichselbaum, R.R., Oligometastases (1995) J Clin Oncol, 13 (1), pp. 8-10; Ost, P., Decaestecker, K., Lambert, B., Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer (2014) Prostate, 74, pp. 297-305; Saluja, R., Cheung, P., Zukotynski, K., Emmenegger, U., Disease volume and distribution as drivers of treatment decisions in metastatic prostate cancer: from chemohormonal therapy to stereotactic ablative radiotherapy of oligometastases (2016) Urol Oncol, 34 (5), pp. 225-232; De Bari, B., Arcangeli, S., Ciardo, D., Extreme hypofractionation for early prostate cancer: biology meets technology (2016) Cancer Treat Rev, 50, pp. 48-60; Nair, R., Lamb, B.W., Geurts, N., The role of local therapy for oligometastatic prostate cancer: should we expect a cure? (2017) Urol Clin North Am, 44 (4), pp. 623-633; Cho, Y., Chang, J.S., Rha, K.H., Does radiotherapy for the primary tumor benefit prostate cancer patients with distant metastasis at initial diagnosis? (2016) PLoS ONE, 11 (1); Riva, G., Marvaso, G., Augugliaro, M., Cytoreductive prostate radiotherapy in oligometastatic prostate cancer: a single centre analysis of toxicity and clinical outcome (2017) Ecancermedicalscience, 30 (11), p. 786; Koo, K.C., Dasgupta, P., Treatment of oligometastatic hormone-sensitive prostate cancer: a comprehensive review (2018) Yonsei Med J, 59 (5), pp. 567-579; Henderson, D.R., Tree, A.C., van As, N.J., Stereotactic body radiotherapy for prostate cancer (2015) Clin Oncol (R Coll Radiol), 27 (5), pp. 270-279; Miralbell, R., Roberts, S.A., Zubizarreta, E., Hendry, J.H., Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9–2.2) Gy (2012) Int J Radiat Oncol Biol Phys, 82 (1), pp. e17-e24; Evangelista, L., Zattoni, F., Guttilla, A., Saladini, G., Zattoni, F., Colletti, P.M., Rubello, D., Choline PET or PET/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis (2013) Clin Nucl Med, 38 (5), pp. 305-314",
year = "2019",
doi = "10.1007/s11547-018-0952-x",
language = "English",
volume = "124",
pages = "211--217",
journal = "Radiol. Med.",
issn = "0033-8362",
publisher = "Springer-Verlag Italia s.r.l.",
number = "3",
}